Article Information
History
- August 21, 2018.
Article Versions
- You are currently viewing Version 1 of this article (August 21, 2018 - 12:19).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Iman Tavassoly1,*,
- Yuan Hu1,2,*,
- Shan Zhao1,*,
- Chiara Mariottini1,
- Aislyn Boran1,
- Yibang Chen1,
- Lisa Li1,
- Rosa E. Tolentino1,
- Gomathi Jayaraman1,
- Joseph Goldfarb1,
- James Gallo1,3 and
- Ravi Iyengar1
- 1Department of Pharmacological Sciences and Systems Biology Center New York, Icahn School of Medicine at Mount Sinai, New York NY 10029
- 2Clinical Pharmacology and Pharmacy, Chinese PLA General Hospital, Beijing, PRC
- 3Present address: Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany NY
- Address correspondence to: Ravi Iyengar, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., Rm 12-70, New York NY 10029, e-mail: ravi.iyengar{at}mssm.edu, Phone: 212-659-1707
Posted August 21, 2018.
Systems therapeutics analyses identify genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer
